A Study to Assess Efficacy and Safety of Baxdrostat in Participants with Primary Aldosteronism - BaxPA

Exclusion Criteria

• - If not taking an MRA or potassium sparing diuretic at Screening: Mean seated SBP > 170 mmHg or mean seated DBP ≥110 mmHg (on AOBPM).
• If taking an MRA or potassium sparing diuretic at Screening: Mean seated SBP > 160 mmHg or mean seated DBP ≥ 100 mmHg.
• - Previous surgical intervention for an adrenal adenoma or have a planned adrenalectomy, renal nerve denervation, or adrenal ablative procedure during the course of the study.
• - Has the following known secondary causes of HTN: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, Cushing’s syndrome, aortic coarctation.
• - Serum sodium level < 135 mmol/L at Screening, determined as per central laboratory.
• - New York Heart Association functional HF class IV at Screening.
• - Persistent atrial fibrillation.
• - Treatment with any MRA or potassium-sparing diuretic within 2weeks prior to Randomisation.